Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome

Journal of Clinical Oncology

Volumn 30, Issue 18, 2012, Pages 2204-2210

  Garcia Manero, Guillermo ^a   Tambaro, Francesco Paolo ^a   Bekele, Nebiyou B ^a   Yang, Hui ^a   Ravandi, Farhad ^a   Jabbour, Elias ^a   Borthakur, Gautam ^a   Kadia, Tapan M ^a   Konopleva, Marina Y ^a   Faderl, Stefan ^a   Cortes, Jorge E ^a   Brandt, Mark ^a   Hu, Yumin ^a   McCue, Deborah ^a   Newsome, Willie Mae ^a   Pierce, Sherry R ^a   De Lima, Marcos ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; IDARUBICIN; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CELLULITIS; COLITIS; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DIARRHEA; DIPLOIDY; DISEASE MARKER; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EDEMA; EVENT FREE SURVIVAL; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPOMAGNESEMIA; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT DISEASE; SKIN TOXICITY; SWELLING; TREATMENT RESPONSE; TYPHLITIS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYDROXAMIC ACIDS; IDARUBICIN; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECURRENCE;

EID: 84864011031     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.3265     Document Type: Article

References (21)

1. Kantarjian HM, Erba HP, Claxton D, et al: Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 28:549-555, 2010
2. Jabbour E, Kantarjian H, Ravandi F, et al: A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 117:1236-1244, 2011
3. Ravandi F, Cortes JE, Jones D, et al: Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 28:1856-1862, 2010
4. Garcia-Manero G, Yang H, Bueso-Ramos C, et al: Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111:1060-1066, 2008 (Pubitemid 351213383)
5. Duvic M, Talpur R, Ni X, et al: Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31-39, 2007 (Pubitemid 46053039)
6. Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, et al: Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 108:1174-1182, 2006 (Pubitemid 44232012)
7. Shiozawa K, Nakanishi T, Tan M, et al: Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Clin Cancer Res 15:1698-1707, 2009
8. Kadia TM, Yang H, Ferrajoli A, et al: A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol 150:72-82, 2010
9. Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organization classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 114:937-951, 2009
10. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079- 2088, 1997
11. Soriano AO, Yang H, Faderl S, et al: Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110:2302-2308, 2007 (Pubitemid 47523148)
12. Wei Y, Kadia T, Tong W, et al: The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin Cancer Res 16:3923-3932, 2010
13. Fernandez HF, Sun Z, Yao X, et al: Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361:1249-1259, 2009
14. Schnittger S, Schoch C, Kern W, et al: Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106:3733-3739, 2005 (Pubitemid 41739006)
15. Damm F, Heuser M, Morgan M, et al: Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood 117:4561-4568, 2011
16. Mizushima N, Levine B, Cuervo AM, et al: Autophagy fights disease through cellular self-digestion. Nature 451:1069-1075, 2008 (Pubitemid 351317450)
17. Gilbert LA, Hemann MT: DNA damage-mediated induction of a chemoresistant niche. Cell 143:355-366, 2010
18. Hu Y, Lu W, Chen G, et al: Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound â-phenylethyl isothiocyanate. Blood 116:2732-2741, 2010
19. Shao Y, Gao Z, Marks PA, et al: Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 101:18030-18035, 2004 (Pubitemid 40054069)
20. Robert T, Vanoli F, Chiolo I, et al: HDACs link the DNA damage response, processing of doublestrand breaks and autophagy. Nature 471:74-79, 2011
21. Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96:4075-4083, 2000